Peptonic Medical AB (publ) ("Peptonic" or the "Company") today announces that the first shipment under the Company's partnership agreement in the United States has now been dispatched. The delivery represents an important milestone in Peptonic's international expansion and marks the transition from the preparation phase to commercial deliveries under the partnership.
The agreement has been entered into with an established US company specialising in intimate self-care for women during and after menopause and covers the United States, Canada, Mexico and the United Kingdom. Peptonic supplies products that will be marketed and sold under the partner's own well-known brand.
The first order was received in October 2025 and has an initial value of USD 120,000. Since then, Peptonic and the partner have worked together on product design, packaging adaptations and other preparations for delivery.
"The completion and dispatch of the first order is a significant step for Peptonic and a tangible result of the work carried out together with our partner. The delivery demonstrates our ability to turn strategic international partnerships into commercial operations and provides an important foundation for continued growth in the US market and the other markets covered by the agreement," says Daniel Rudeklint, interim CEO of Peptonic Medical.
The Company's growth strategy is based on geographic expansion, strategic partnerships and product development. By combining Peptonic's product development and medical technology expertise with the partner's established market presence, the collaboration creates opportunities to reach more women with effective, gentle and science-based intimate self-care products.
For further information, please contact:
Daniel Rudeklint, interim CEO, Peptonic Medical AB
Email: daniel.rudeklint@peptonicmedical.se
Telephone: +46 73 158 02 73
About Peptonic Medical AB
Peptonic Medical AB (publ) is a Swedish medical technology company that develops and sells clinically proven self-care products for women's intimate health. Under the VagiVital and Vernivia brands, the Company offers an over-the-counter portfolio of effective and gentle products that help women understand, treat and prevent common intimate health conditions. Peptonic's growth strategy is based on geographic expansion, particularly in the United States and Europe, and on continuously strengthening its product portfolio through in-house product development and strategic acquisitions.